SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
← catalyst calendarSponsored by Palvella Therapeutics, Inc. (industry) · PVLA — their whole pipeline →. With FDA Office of Orphan Products Development.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
51actual
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-31 | actual | When the study began enrolling |
| Primary completion | 2026-01-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Microcystic Lymphatic Malformation
Intervention
- Drug: QTORIN 3.9% Rapamycin Anhydrous Gel
Primary outcome
what the primary-completion date above is the date OFOverall microcystic lymphatic malformations Investigator Global Assessment (mLM-IGA)
measured At Week 24
Permalink · PVLA's whole pipeline · Catalyst calendar · Every registered study · What changed